Broadwood Capital Inc Q3 2022 vs. Q4 2022 13F Holdings Comparison
Ava Hoppe | 9 May, 2023
Broadwood Capital Inc is a hedge fund investment firm based in New York City. This article will compare its Q3 2022 and Q4 2022 13F holdings, which are public disclosures required by the Securities and Exchange Commission (SEC). The following is a summary of the holdings, changes, and trends between the two quarters.
MNST - Monster Beverage Corp New
Broadwood Capital Inc maintained its position in Monster Beverage Corp New at 4,656,488 shares, with a value of $404,928 in Q3 2022, and $472,773 in Q4 2022, a 16.8% increase.
STAA - Staar Surgical Co
Broadwood Capital Inc increased its holdings in Staar Surgical Co from 8,592,007 shares in Q3 2022 to 8,783,082 shares in Q4 2022, a 2.2% increase. However, the value of the holdings decreased from $606,166 in Q3 2022 to $426,330 in Q4 2022, a 29.7% decline.
AXON - Axon Enterprise Inc
Broadwood Capital Inc maintained its position in Axon Enterprise Inc at 760,062 shares, with a value of $87,977 in Q3 2022 and $126,117 in Q4 2022, a 43.4% increase.
IWM - Ishares Tr
Broadwood Capital Inc maintained its position in Ishares Tr at 690,000 shares, with a value of $113,795 in Q3 2022 and $120,308 in Q4 2022, a 5.7% increase.
LCTX - Lineage Cell Therapeutics In
Broadwood Capital Inc maintained its position in Lineage Cell Therapeutics In at 34,935,485 shares, with a value of $39,477 in Q3 2022 and $40,874 in Q4 2022, a 3.5% increase.
OCX - Oncocyte Corp
Broadwood Capital Inc maintained its position in Oncocyte Corp at 23,353,697 shares, with a value of $17,048 in Q3 2022 and $7,494 in Q4 2022, a 56% decrease.
AGE - Agex Therapeutics Inc
Broadwood Capital Inc maintained its position in Agex Therapeutics Inc at 2,997,156 shares, with a value of $1,683 in Q3 2022 and $1,654 in Q4 2022, a 1.7% decrease.
BTRS Holdings Inc
Broadwood Capital Inc sold all of its 4,229,652 shares in BTRS Holdings Inc in Q4 2022, down from 4,229,652 shares in Q3 2022. The value of the holdings was $39,167 in Q3 2022 and $0 in Q4 2022, a 100% decrease.
In conclusion, Broadwood Capital Inc increased its holdings in four stocks, maintained its positions in four stocks, and sold all of its holdings in one stock between Q3 2022 and Q4 2022. Despite the fluctuations in value, Broadwood Capital Inc seems to believe in the long-term potential of these stocks.
Other Posts
- HS Management Partners, LLC Q2 2023 vs. Q3 2023 13F Holdings Comparison
- Analyzing Moisand Fitzgerald Tamayo, LLC's Q3 vs. Q4 2022 Portfolio Changes: ETFs and Company Holdings.
- The Rise and Fall of Starboard Value LP Q3 2022 vs. Q4 2022 13F Holdings
- Twele Capital Management, Inc. Q4 2022 vs. Q1 2023: An Overview of 13F Holdings Update
- Investment Analysis: Parkside Advisors LLC Q4 2022 vs. Q1 2023
- The Dramatic Shift in Turim 21 Investimentos Ltda.'s Q3 vs. Q4 2022 13F Holdings
- EyeSouth Partners Affiliates With Atlantic Eye Institute, Expanding Their Premier Network of Eye Care Services
- Options Technology Announces Jenni Sellick as Vice President, Legal and Commercial Manager
- Hunt Lane Capital LP's Significant Shift: Selling All Shares in Top Companies, Showing Bearish Stance in Q4 2022
- Revolutionary Changes: Comparing Worm Capital's 13F Holdings in Q3 2022 vs Q4 2022